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A B S T R A C T
For an effective detection of doping with pseudo-endogenous anabolic steroids, the urinary steroid profile is of
high value. In this work, the aim was to investigate steroid metabolism disruption after exogenous intramuscular
administration of different testosterone esters. The investigation focused on both sulfo – and glucoro conjugated
androgens. A single intramuscular injection of either 1000 mg testosterone undecanoate (Nebido®) or a mixture
of 30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaproate, and
100 mg testosterone decanoate (Sustanone®), was given to six healthy volunteers. Urine was collected
throughout a testing period of 60 days. A LC-MS method was developed and validated for the analysis of eight
conjugated steroids in their intact form. The results show that urinary changes in both sulfo – and glucuro
conjugated steroid levels are prominent after the injection of testosterone esters. A promising potential marker
for the intake of exogenous testosterone is the combined ratio of epitestosterone sulfate/epitestosterone glu-
curonide to testosterone sulfate/testosterone glucuronide ((ES/EG)/(TS/TG)) as a complementary biomarker for
testosterone abuse. This represents a new piece of evidence to detect testosterone doping, representing a new
approach and being independent from the metabolic connections of the markers in the steroid passport.
1. Introduction
The most frequently banned substances detected in anti-doping la-
boratories are anabolic steroids [1]. The intake of anabolic steroids
alters the endogenous steroid profile, especially when pseudo-en-
dogenous steroids like testosterone or testosterone derivatives are used.
Hence, urinary steroid profiling is a powerful tool to detect the misuse
of pseudo-endogenous anabolic steroids in sports [2]. Today, the profile
consists of concentrations and ratios of various endogenously produced
steroidal hormones, as well as their precursors and metabolites [3]. In
2014, the steroidal module of the Athlete Biological Passport (ABP) was
implemented in doping control procedures [4,5]. This includes a
longitudinal follow up of the individual athlete’s steroid profile, which
increases the sensitivity for detecting alterations, compared to the use
of solely population reference values.
Most anabolic steroids are extensively metabolized in the human
body [6,7]. The metabolism includes phase I, as well as phase II
transformations, and most endogenous steroids are excreted in urine in
conjugated form. Two major pathways are involved in the conjugation;
one leads to the formation of glucuronides and requires uridine di-
phosphoglucuronic acid (UDPGA) and a glucuronyl transferase. The
other pathway leads to the formation of sulfates and a family of en-
zymes called sulfotransferases (SULTs) mediates the reaction. SULTs
catalyze the transfer of sulfonate (–SO3−) from the universal sulfonate
donor 3′-phosphoadenosine 5′-phosphosulfate (PAPS) to the hydroxyl
or amino group of an acceptor molecule [8]. The subfamilies of the
cytosolic SULTs are responsible for the conjugation of steroids.
Today, the steroid profiling mainly relies on the analysis of glu-
curonide metabolites. After the selective hydrolysis of the glucuronide
moiety, the corresponding free steroid is analysed by gas chromato-
graphy – mass spectrometry (GC–MS) subsequent to silylation of hy-
droxyl – and keto-groups [2,3]. The inclusion of sulfate metabolites has
previously been difficult due to a non-efficient hydrolysis to the cor-
responding phase I metabolites. Consequently a potenially important
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piece of information about alterations in the steroid metabolism after
testosterone doping is not monitored so far. However, during the last
years, the direct analysis of phase II steroid metabolites by liquid
chromatography – mass spectrometry (LC-MS) has been described in
numerous reports [9–23].
Although the current strategy in steroid profiling represents an ef-
ficient detection of doping with endogenous steroids, there are still
challenges in revealing for instance doping with some low-dose ad-
ministration forms. Hence, additional approaches are needed to im-
prove the detection capabilities within the steroidal passport.
The aim of this study was therefore to explore the impact of en-
dogenous sulfate steroid metabolites on the steroid profile after the
intramuscular administration of a single dose of testosterone esters to
six healthy volunteers. We wanted to investigate how both android
sulfates and android glucuronides are affected by the intake of exo-
genous testosterone, including the ratios between them. For this pur-
pose, a fully validated LC-MS method for the simultaneous determina-
tion of 8 different sulfate- and glucuronide-conjugated steroids was
developed and applied. The steroids included in the study were: tes-
tosterone glucuronide (TG), epitestosterone glucuronide (EG), andros-
terone glucuronide (AG), etiocholanolone glucuronide (EtioG), testos-
terone sulfate (TS), epitestosterone sulfate (ES), androsterone sulfate
(AS), and etiocholanolone sulfate (EtioS).
2. Experimental
2.1. Chemicals and reagents
Reference conjugated steroid analytes and internal standards were
purchased from The National Measurement Institute (NMI) (Sydney,
Australia), except D5-AG, which was synthesized at the Vienna
University of Technology (Vienna, Austria). All steroid solutions were
prepared in isopropanol and stored at −20 °C. Working solutions were
obtained by diluting stock solutions. Water and acetonitrile were of
HPLC grade and was provided by Biosolve Chimie (Dieuze, France).
Methanol of HPLC grade was obtained from Chem Lab (Zedelgan,
Belgium) and Formic acid (99%, ULC/MS-CC/SFC) was purchased from
Bisolve (Valkenswaard, The Netherlands). Potassium dihydrogen
phosphate, sodium chloride, di-sodium hydrogen phosphate, and am-
monium chloride, were obtained from Merck (Darmstadt, Germany).
Urea was provided by GE Healthcare Life Sciences (Uppsala, Sweden)
and creatinine was purchased from Sigma Aldrich (St. Louis, MI, USA).
SPE Oasis HLB cartridges (60 mg, 30 µm particle size) was obtained
from Waters (Milford, MA, USA).
An internal standard (IS) solution was prepared in methanol with
the following concentrations: 1.8 µg/ml D3-TG, 1.8 µg/ml D4-EG,
56 µg/ml D5-AG, 51 µg/ml D5-EtioG, 0.7 µg/ml D3-TS, 0.7 µg/ml D3-ES,
15 µg/ml D4-AS, and 15 µg/ml D5-EtioS. The solution was stored in the
dark at −20 °C.
2.2. Sample preparation
A loading solution for solid phase extraction (SPE) was prepared by
adding 25 µl of the IS solution to 2 ml of urine. The extraction was
performed on Oasis HLB cartridges (60 mg, 30 µm particle size) and
carried out as follows: cartridges were first conditioned with 2 ml of
methanol and equilibrated with 2 ml of water. The loading solution was
added, followed by washing with 2 ml of water. Finally, the analytes
were eluted with 2 ml of methanol. The eluate was evaporated to
dryness and reconstituted with 150 µl Acetonitrile/Water (20:80, v/v).
2.3. Instrumentation
The analysis was carried out on a Q Exactive orbitrap mass spec-
trometer coupled to a Vanquish Horizon UHPLC System (Thermo
Fisher, Austin, TX, USA). The system was equipped with an autosampler
with a temperature controlled sample tray set at 20 °C and a column
oven set at 25 °C. Chromatographic separation was performed using a
Phenomenex Kinetex C18 column (150 × 2.1 mm i.d., 1.7 µm particle
size). The mobile phase was composed of water containing 0.1% formic
acid (solvent A) and acetonitrile containing 0.1% formic acid (solvent
B). A gradient elution program was employed at a constant flow rate of
0.3 ml/min with solvent B starting at 25% for 2 min; 2–12.5 min,
25–39% B; 12.5–13.5 min, 39–98% B; 13.5–15 min, 98% B. The column
was finally re-equilibrated at 25% B for 3 min.
The mass spectrometer was equipped with a heated electrospray
ionization (HESI) source, operated in the negative mode. Source para-
meters were as follows: spray voltage 2.8 kV, capillary temperature
320 °C, sheath gas and auxiliary gas (nitrogen): 30 and 10 arbitrary
units, respectively. The instrument was operated in the FS mode from
m/z 100–700 at 70 000 resolving power.
2.4. Validation
Validation of the analytical assay was carried out in compliance
with the International Standard for Laboratories (ISL) of the World
Anti-Doping Code [24]. The matrix used for the validation study and for
the preparation of calibration curves was an artificial urine prepared in
the laboratory (2.5 g/L potassium dihydrogen phosphate, 9.0 g/L so-
dium chloride, 2.5 g/L di-sodium hydrogen phosphate, 3.0 g/L
Table 1
Validation data for TS, ES, AS, EtioS, TG, EG, AG, and EtioG.
TS ES AS EtioS TG EG AG EtioG
Linearity (r2) 0.9995 0.9994 0.9992 0.9982 0.9992 0.9992 0.9927 0.9984
LOQ (ng/ml) 0.4 0.4 9 8 1 0.6 30 29
Recovery (%) 99 99 99 99 99 99 99 98
Carry-over (%) <0.1 < 0.1 < 0.1 <0.1 < 0.1 < 0.1 <0.1 < 0.1
Repeatability (RSD%)
Calibration level 1 4.0 4.2 2.8 3.5 3.9 5.2 3.3 3.8
Calibration level 3 1.0 0.9 3.4 1.0 1.4 1.8 1.9 1.3
Inter-assay precision (RSD%)
Calibration level 1 9.6 9.4 7.1 8.0 9.5 10.6 11.3 10.3
Calibration level 3 3.1 3.3 3.2 2.4 3.2 3.8 3.1 3.1
Robustness (RSD%)
Precision 0.6 1.0 0.8 0.7 1.5 1.8 2.7 1.3
Retention time <0.1 < 0.1 < 0.1 <0.1 < 0.1 < 0.1 <0.1 < 0.1
Accuracy (% recovery)
Calibration level 3 96 97 103 100 99 100 101 101
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ammonium chloride, 25 g/L urea, and 2 g/L creatinine, prepared in
water).
The calibration was established over the range of 1–600 ng/ml for
TG, 0.6–372 ng/ml for EG, 0.5–300 ng/ml for TS and ES, 30–3000 ng/
ml for AG and EtioG, and finally 10–6000 ng/ml for AS and EtioS. Each
calibration curve consisted of seven calibration levels. The calibration
curves were built from the peak area ratio of the conjugated steroids
versus the deuterated internal standard. The limit of quantification
(LOQ) was determined as the lowest calibration point for which an
acceptable precision was tested and proven.
Matrix effects were assessed by comparison of the slopes of the
calibration curves of artificial urine standards with the slopes of the
calibration curves of standards in water. In addition, chromatograms
generated from urine samples were visually inspected for interfering
signals, in order to evaluate matrix interferences and specificity.
Repeatability was evaluated at two different concentration levels
(level 1 and level 3) with 10 independent spiked artificial urine samples
on each level (Level 1 (ng/ml); TS: 0.4, ES: 0.4, AS: 9, EtioS: 8, TG: 1,
EG: 0.6, AG: 30, EG: 29. Level 3 (ng/ml); TS: 8, ES: 8, AS: 189, EtioS:
157, TG: 20, EG: 12, AG: 600, EG: 573). The analysis was performed on
the same day. Inter-day precision was performed by repeating the ex-
periment on three consecutive days.
Fig. 1. UPLC-MS extracted chromatograms of A: Extracted blank artificial urine sample, B: Extracted spiked artificial urine sample (level 3), C: Extracted urine
sample collected 1 h after intramucular administration of Sustanon®. 1: Testosterone sulfate (TS), 2: D3-Testosterone sulfate (D3-TS), 3: Epitestosterone sulfate (ES),
4: D3-Epiestosterone sulfate (D3-ES), 5: Androsterone sulfate (AS), 6: D4-Androsterone sulfate, 7: Etiocholanolone sulfate (EtioS), 8: D5-Etiocholanolone sulfate (D5-
EtioS), 9: Testosterone glucuronide (TS), 10: D3-Testosterone glucuronide (D3-TG), 11: Epitestosterone glucuronide (EG), 12: D4-Epitestosterone glucuronide, 13:
Androsterone glucuronide, 14: D5-Androsterone glucuronide (D5-AG), 15: D5-Etiocholanolone glucuronide (EtioG), 16: D5-Etiocholanolone glucuronide (D5-EtioG).
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Accuracy was assessed by comparing the theoretical amount of
analyte to the actually quantified value in the repeatability studies.
To ensure that the developed method was robust to small variations
in various sample – and preparation conditions, robustness was tested
by extracting artificial urine samples at different pH values (pH 5, pH 7,
and pH 9). Each variation was tested on two different concentration
levels (level 1 and level 3).
Carry-over during instrumental analysis was evaluated by injecting
a high concentrated artificial urine sample prior to the injection of two
consecutive blank water samples.
Extraction recoveries were investigated in urine samples by com-
paring responses of deuterated internal standards (D3-TG, D4-EG, D5-
AG, D5-EtioG, D3-TS, D3-ES, D4-AS, D5-EtioS) that were spiked in urine
samples before and after the extraction (25 µl of the IS solution).
2.5. Clinical study design
The study was an open-label, parallel group investigation with six
healthy volunteers. All participants were male, in good health, and
submitted to a clinical evaluation before they were included in the
study. Written consent was obtained, allowing the use of collected
samples for research purposes.
Each volunteer was randomly assigned to either a single in-
tramuscular injection of testosterone undecanoate 1000 mg (Nebido®)
or a single intramuscular injection of a mixture of four testosterone
esters: testosterone propionate 30 mg, testosterone phenylpropionate
60 mg, testosterone isocaproate 60 mg and testosterone decanoate
100 mg (Sustanon®). Three subjects were assigned to each study group.
The collection of urine samples was performed predose (3 samples;
day -2, day -1 and day 0) and at the following times after dose ad-
ministration: 1, 4, 8 and 12 h (day 0), followed by sampling at day 1, 2,
3, 4, 5, 6, 8, 11, 15, 18, 22, and 60.
The study was approved by the Local Review Board and Ethics
Committee of Children’s Hospital Srebrnjak (Zagreb, Croatia) and the
Croatian Central Ethics Committee, and conducted according to the
Helsinki declaration.
2.6. Data analysis
All urinary concentrations were corrected for specific gravity [3].
Distribution of data was assessed using the normality tests Shapiro-
Wilks and Kolmogorov-Smirnov. Furthermore, histograms were used to
evaluate model assumptions. Non-parametric Wilcoxon signed-rank test
was used to assess changes after treatment with testosterone esters.
Base-line values (average of three values), recorded before the testos-
terone ester application, were compared to post-administration values.
Post-administration values were recorded from the samples collected
during the first 11 days subsequent to drug administration (average of
twelve values). A p-value below 0.05 was regarded as statistically sig-
nificant. Data analysis were performed using SPSS statistical software
version 25 (IBM Corporation, New York, USA) and Xcalibur (Thermo
Fisher, Austin, TX, USA)
3. Results and discussion
3.1. Validation
The method validation performance criteria were evaluated by as-
sessing linearity, LOQ, specificity, matrix effects, repeatability (% RSD),
inter-assay precision (% RSD), accuracy (as % recovery of theoretical
value), carry-over (%), and extraction recovery. In general, the assay
validation demonstrated good performance for all tested analytes. The
results are summarized in Table 1.
All calibration curves had a coefficient of determination
(R2) > 0.99, which indicated excellent linearity within the respective
calibration range for each validated compound. A narrower calibration
range was applied for AG and EtioG, compared to AS and EtioS, due to a
lower linear range. LOQ was between 0.4 ng/ml and 30 ng/ml. The
assay showed good specificity with no interfering peaks observed at the
expected retention times of TS, ES, AS, EtioS, TG, AG, and EtioG. An
interfering peak was, however, observed close to the EG retention time
in urine. Nevertheless, the quantification could be carried out with
sufficient accuracy and precision, and the values matched corre-
sponding values generated by previous GC–MS measurements. By
comparing slopes of the calibration curves from calibration standards in
artificial urine and water, only a slight to moderate variation could be
observed. Nevertheless, all calibrations in the study were performed in
artificial urine and exclusively isotopically labelled internal standards
(IS) were utilized for the quantification. The calculated values for re-
peatability and inter-assay precision are within acceptable ranges for all
substances. Furthermore, the method demonstrated sufficient accuracy,
no sample carry over and excellent recoveries. Extracting samples with
different pH-values yielded low RSD variation in measured urine con-
centrations, as well as in retention times (RT). Hence, robustness of the
procedure is ensured.
In Fig. 1, extracted ion chromatograms generated during the vali-
dation procedure, as well as during the analysis of urine samples from
the clinical study, are shown. They represent a blank artificial urine
Table 2
Statistical significance of tested parameters in the clinical study.
Wilcoxon signed-rank test: Base-line
values compared to post administration
values (11 days)
Direction of change
Testosterone sulfate (TS) significant change decrease
Epitestosterone sulfate (ES) significant change decrease
Androsterone sulfate (AS) – –
Etiocholanolone sulfate (EtioS) – –
Testosterone glucuronide (TG) significant change increase
Epitestosterone glucuronide (EtioG) significant change decrease
Androsterone glucuronide (AG) – –
Etiocholanolone glucuronide (EtioG) – –
TG/EG significant change increase
TS/TG significant change decrease
ES/EG significant change increase
AS/AG – –
EtioS/EtioG – –
AG/TG significant change decrease
AS/TS significant change increase
(ES/EG)/(TS/TG) significant change increase
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Fig. 2. Urinary androgen sulfate excretion during 60 days after administration of Sustanon or Nebido. P1: Participant 1, P2: Participant 2, P3: Participant 3, P4:
Participant 4, P5: Participant 5, P6: Participant 6.
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Fig. 3. Urinary androgen glucuronide excretion during 60 days after administration of Sustanon or Nebido. P1: Participant 1, P2: Participant 2, P3: Participant 3, P4:
Participant 4, P5: Participant 5, P6: Participant 6.
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sample, a spiked artificial urine sample at calibration level 3, and a
urine sample from the clinical study. In conclusion, the analytical assay
proved to be fit for purpose.
3.2. Steroid profiles
Intramuscular administration of testosterone esters resulted in nu-
merous changes in the steroid profile. This includes both ratios and
concentrations of conjugated steroids. The investigated parameters
were the urinary concentrations of TG, EG, AG, EtioG, TS, ES, AS and
EtioS, in addition to the ratios TG/EG, TS/TG, ES/EG, AS/AG, EtioS/
EtioG, AG/TG, AS/TS, and finally the combined ratio (ES/EG)/(TS/TG).
Altogether, 10 of the investigated parameters showed significant
changes after administration of testosterone. A significant increase was
observed for the urinary levels of TG, TG/EG, (ES/EG)/(TS/TG), and
AS/TS, whereas the urinary levels of EG, TS, ES, TS/TG, and AG/TG
were significantly decreased. The results are summarized in Table 2. In
Figs. 2–5, the excretion profiles for all tested conjugated steroids, in
addition to ratios are illustrated. The baseline values are average values
from the three urine samples collected before the administration of
testosterone esters.
The changes observed for the urinary levels of the measured glu-
curonides are expected [2,25,26]. In abusers of testosterone, the con-
centration of TG in urine is normally increased. EG, on the other hand,
is not a metabolite of exogenous testosterone and it is not unusual to see
a diminished excretion by negative feedback. Hence, the testosterone/
epitestosterone ratio of the combined free and glucuronide fractions is
one of the most important markers of testosterone abuse in doping
analysis today [3,27]. The excretion of free testosterone and epites-
tosterone in urine is negligible, thus the ratio TG/EG is equivalent to the
ratio applied in routine doping analysis. Not surprisingly, this ratio
increased significantly in our study. Furthermore, the testosterone
metabolites AG and EtioG showed an increase in urinary excretions
after the administration of Sustanon®, but not for Nebido®. The reason
for this is that these two preparations have quite different absorption
characteristics. The depot effect of the testosterone ester preparations
increases in proportion to the length of the ester side chains [28].
Sustanon® is a mixture of fast – and long acting testosterone esters.
Nebido®, on the other hand, only contains the long-acting ester tes-
tosterone undecanoate. Hence, a peak in AG and EtioG concentrations
could not be detected. Not surprisingly, however, more prominent
changes were observed for the AG/TG ratio, which significantly de-
creased.
The aim of this study was to explore the implementation of sulfate
androgen metabolites in the steroid profile. One of the most abundant
changes in sulfate metabolites could be observed in the concentration
levels of TS. Interestingly, the levels decreased after intramuscular ad-
ministration of the preparations. This can most likely be explained by a
low sulfatation of exogenous testosterone in the human body. The
reason is that endogenous testosterone is mainly sulfated by subfamilies
of SULTs that are present in the testis, which is the main production site
for testosterone in the male human body. It has previously been shown
that approximately 95% of TS and 70% of ES are of testicular origin
[29]. The decreased concentration levels of TS might be due to a
feedback inhibition of luteinizing hormone (LH), initiated by the exo-
genous testosterone intake. This has also been suggested by Schulze
et al in 2011 who examined androgen sulfatation in association with
gene polymorphism [30]. Like in our study, they also observed a de-
crease in TS levels subsequent to an intramuscular administration of a
testosterone ester.
In another study, though, comprising a single oral dose of testos-
terone undecanoate, Esquivel et al reported an increase of urinary TS
concentration values [12]. This result is contrary to our observation.
Nevertheless, a crucial difference between the two studies is the route
of administration. In our study, all testosterone esters were adminis-
tered as intramuscular injections, whereas in the study of Esquivel et al,
testosterone undecanoate was given orally. By oral administration,
drugs are absorbed from the gastrointestinal tract and pass via the
portal vein to the liver where some drugs are metabolized (first pass
metabolism). During the gastrointestinal absorption of a drug, the
concentration in the liver is high. Hence, liver passage and first pass
metabolism might be one explanation for the different observations. In
the case of oral administration, the metabolism could switch towards
sulfatation due to saturation processes in the liver caused by the high
concentration of the drug.
In our study, both EG and ES significantly decreased subsequent to
testosterone administration. Already in 1996, Dehennin et al proposed
to include ES in the steroid profile in sports drug testing. They sug-
gested that the ratio of TG and total epitestosterone (glucuronides and
sulfates) would better discriminate between physiologically high and
pharmacologically high T/E-ratios [31]. It was proposed that naturally
low levels of EG could be attributed to a dysregulation in the secretion
of epitestosterone by the testis which implies that the secretion of EG is
decreased and the secretion of ES is normal or increased [32]. An al-
ternative explanation was suggested to be a deficiency of a specific
sulfatase, leading to less circulating epitestosterone available for he-
patic glucuronidation [32].
Nevertheless, in steroid profiling, steroid ratios seem to be superior
to steroid concentrations. In this study, a number of ratios were ex-
plored. After intramuscular administration of testosterone esters, the
most abundant decrease was seen in the ratio TS/TG, in addition to an
increase in the well characterized ratio of TG/EG. As already outlined,
it seems to be a shift towards glucuronidation of testosterone.
Furthermore, as already mentioned, a decrease in the urinary excretion
of ES, as well as EG, was observed. Since the ratio ES/EG is decreased,
the suppression of EG seems to be more pronounced than ES.
In the light of these results, we propose the combination of the ratios
ES/EG and TS/TG ((ES/EG)/(TS/TG)) as a complementary biomarker
for testosterone abuse. After injection of Sustanon®, the ratio reached
its maximum value between 3 and 11 days. The changes in the ratio
was, however, already detectable from the same day of injection of the
ester. Subsequent to the administration of Nebido®, the raise in the (ES/
EG)/(TS/TG) ratio was slightly delayed, compared to the results from
the Sustanon® study. In this case, the maximum value was recorded
between 6 and 22 days.
In Fig. 6, T/E-ratios are compared to (ES/EG)/(TS/TG)-ratios for all
six participants. In window A, the calculated ratios are shown, whereas
normalized values are pictured in window B. For each participant, the
values in window B are normalized to calculated ratios at time point
zero, which are considered the baseline values. Elevated ratios were
observed in approximately the same time window, comparing T/E - and
(ES/EG)/(TS/TG)- ratios. It is, however, of high interest that the in-
crease in normalized (ES/EG)/(TS/TG) ratios are clearly higher than
normalized T/E- ratios for participants 1, 2, 3 and 6. This might suggest
the (ES/EG)/(TS/TG)- ratio to be a more sensitive marker than the T/E-
ratio for some individuals.
Noteworthy, the urinary AS/TS ratio also increased for all partici-
pants. The increase was in particular remarkable between 2 and 22 days
after application of the preparations. Nevertheless, we do not consider
this ratio as suitable for the detection of testosterone misuse as the
combined ratio (ES/EG)/(TS/TG). AS/TS is most likely not sensitive
after oral intake of testosterone, since an increase in TS is expected. The
(ES/EG)/(TS/TG) ratio, on the other hand, also includes the glucuro-
nated steroids, and consequently takes into account changes in both
Fig. 4. Urinary androgen conjugate excretion ratios during 60 days after administration of Sustanon or Nebido. TS: Testosterone sulfate, TG: Testosterone glucur-
onide, ES: Epitestosterone sulfate, EG: Epitestosterone glucuronide, AS: Androsterone sulfate, AG: Androsterone glucuronide, EtioS: Etiocholanolone sulfate, EtioG:
Etiocholanolone glucuronide.
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sulfatation and glucuronidation.
This study only included one route of administration (in-
tramuscular) and exclusively male participants. Important for future
investigations is to focus on additional routes of administration, like for
instance oral and dermal applications. Additionally, the influence of
potential confounding factors [25] on the (ES/EG)/(TS/TG) ratio
should be explored. Furthermore, female steroid profiles should be in-
cluded in future studies.
4. Conclusion
In conclusion, sulfoconjugated metabolites are relevant for the in-
terpretation of steroid profiles. In this study, a LC-MS method was de-
veloped and validated, and allowed for the quantification of eight
conjugated steroids within the same run. Among the targeted glucuro
-or sulfo -conjugated steroids, their ratios seem to be superior to ab-
solute urinary concentrations as indicators for testosterone ester con-
sumption. The ratio (ES/EG)/(TS/TG) is suggested as a potential bio-
marker for exogenous intake of testosterone.
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